Primary source: Biologics Guidances
Sign in with your work email to save this update, triage it, and track follow-up.
Sign in to saveThe FDA issued multiple new guidance documents, including recommendations for the development of systems for blood component manufacturing, updated FAQs for gene therapy products, and considerations for container closure systems for human drugs and biological products. These documents provide detailed compliance expectations for various product types and clinical trial eligibility criteria.
These updates serve to clarify expectations and requirements for regulatory compliance across multiple sectors of the industry, impacting workflows related to labeling and inspection readiness. Adhering to these guidances is crucial for maintaining compliance with FDA regulations and ensuring product safety.
Sign in to unlock the full action card and owner assignment.
Sign in with your work email to read the full operational brief, action card, and evidence ledger.
Sign in with your work email to unlock the full briefing, regulatory action card, evidence ledger, and role-specific next steps.
PV teams should update workflows and SOPs to include the new section 19A approval processes and ensure compliance with the TGA's guidelines for managing medicine shortages.
PV teams should update their workflows regarding inspection readiness, review standard operating procedures (SOPs) to align with the new GCP inspection coordination processes, and ensure that all relevant personnel are trained on the updated guidance.
PV teams should review and update their Standard Operating Procedures (SOPs) related to real-world data collection methodologies and ensure alignment with the new guidance emerging from the workshop. Training may also be required to enhance understanding of RWD's impact on regulatory submissions.
PV teams should update their regulatory intelligence monitoring workflows to include the timelines and requirements established by the EMA for thalassaemia treatments. It's essential to ensure adherence to the new guidelines in clinical trial designs.
